共 5 条
[1]
Sustained clinical efficacy demonstrated by the selective co-stimulation modulator abatacept (CTLA4) in combination with methotrexate at 2 years in rheumatoid arthritis patients with an inadequate response to metho-trexate. KREMER J,SHERGY W,TINDALL E,et al. Arthritis and Rheumatism . 2004
[2]
Co-stimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA4Ig and LEA29Y eighty-five days after the first infusion. MORELAND LW,ALTEN R,VAN DEN BOSCH F,et al. Arthritis and Rheumatism . 2002
[3]
Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphomide. DAIKH DI,WOFSY D. J Immunol . 2001
[4]
A pilot, multi-center , randomized, double-blind, placebo controlled study of a co-stimulation blocker CTLA4Ig (2mg/kg) given monthly in combination with etanercept in active rheumatoid arthritis. WEINBLATT M,SCHIFF M,GOLDMAN M,et al. Arthritis and Rheumatism . 2002
[5]
Treatment of murine lupus with CTLA4Ig. FINCK BK,LINSLEY PS,WOFSY D. Science . 1994